All Precision Medicine articles
-
ArticlePomegranate-derived compound shows therapeutic potential in heart disease
Researchers at Cardiff University have identified urolithin A – a compound produced by gut bacteria during the metabolism of substances found in pomegranates – as a potential new approach for treating cardiovascular disease.
-
NewsFerroptosis emerges as strategy against treatment-resistant digestive cancers
Researchers are investigating ferroptosis, an iron-dependent cell death pathway, as a potential approach to overcome treatment resistance in digestive cancers.
-
NewsGene-based CIN score predicts breast cancer survival and immunotherapy response
A 13-gene chromosomal instability scoring system developed by Shanghai researchers correlates with survival outcomes and immunotherapy response in breast cancer patients.
-
ArticleMachine learning identifies biological signals linked to emotional hunger
Researchers at Phenomix Sciences are using machine learning and genetic risk scoring to investigate emotional hunger, an obesity phenotype linked to emotional and reward-driven eating behaviours. Dr Timothy O’Connor discusses how the approach could improve patient stratification, obesity research and treatment selection.
-
NewsMetabolic vulnerabilities identified in rare Fibrolamellar liver cancer
Researchers have identified metabolic vulnerabilities in Fibrolamellar cancer, a rare liver malignancy affecting adolescents and young adults, using functional profiling and mass spectrometry. The findings suggest chemotherapy-resistant tumours may be susceptible to metabolism-targeted therapies.
-
ArticleBeyond tangles: why soluble intracellular tau should guide drug discovery
Tau tangles are a hallmark of Alzheimer’s disease and related disorders, but evidence suggests the real damage may come from rare, soluble tau species inside neurons. Targeting these hidden drivers of circuit dysfunction could be key to restoring memory and cognition.
-
ArticleWhy AI models need patient data to deliver in drug discovery
Despite rapid advances in AI, many drug discovery models still struggle to translate computational predictions into clinical outcomes. Thomas Clozel explains how Owkin is training AI on large-scale patient-derived data while integrating experimental and clinical validation directly into model development.
-
NewsASGCT 2026 Annual Meeting opens in Boston this week
The American Society of Gene & Cell Therapy’s 2026 Annual Meeting opens in Boston on 11 May, bringing together thousands of researchers, clinicians and industry leaders for five days of scientific programming.
-
ReportOrganoids and Organ Chips: Improving Decision-Making in Early Drug Discovery
Traditional preclinical models do not always predict what will happen in patients. This report explores how organoids, organ-on-chip systems and advanced imaging are being used to generate more clinically relevant insights and support better decision-making earlier in drug discovery.
-
NewsMachine learning identifies five distinct Parkinson’s disease subtypes
A new study from VIB and KU Leuven has revealed that Parkinson’s disease comprises five distinct molecular subtypes, each requiring tailored therapeutic approaches.
-
ArticleBeyond serendipity: rational design and AI’s expansion of the undruggable target landscape
For decades, drugging the ‘undruggable’ was thought to require luck rather than logic. Today, AI is transforming serendipity into strategy by enabling rational, data-driven approaches to previously inaccessible targets.
-
NewsChampions Oncology to present eight studies at AACR 2026
Champions Oncology will present eight studies at AACR 2026 spanning KRAS-mutant tumours, ovarian cancer, glioblastoma and emerging therapies including radiopharmaceuticals and CAR-T, using patient-derived models to improve early-stage decision-making in oncology drug development.
-
NewsZebrafish drug screening identifies precision therapies for autism
Yale University researchers have created a behavioural drug screening database using zebrafish models to identify FDA-approved compounds that reverse disrupted behaviours linked to autism risk genes.
-
NewsDNA-based system delivers targeted cancer drugs via biomarker logic
Researchers at the University of Geneva have developed a DNA-based drug delivery platform that uses molecular logic gates to identify cancer cells through dual biomarker recognition. The system activates cytotoxic agents only when both tumour markers are present, offering enhanced specificity over current antibody–drug conjugates while enabling deeper tissue penetration and multi-drug combinations.
-
ReportCRISPR & Genomics: Turning Data into Confident Drug Discovery Decisions
Early drug discovery has no shortage of genomic data, but confidence remains scarce. This report examines how CRISPR, functional genomics and human-relevant models are being applied to determine which signals matter, how they influence disease biology and which targets and strategies are worth pursuing.
-
NewsSonoPIN ultrasound method shows promise for targeted cancer therapy
A new ultrasound-based technique developed by researchers at Duke University uses microbubbles to deliver cancer drugs directly into tumour cells, showing promise for highly targeted treatments that cause minimal damage to healthy tissue.
-
ArticleDesigning targeted assays for clinical success from the start
Why do some targeted assays move smoothly from discovery to clinical practice while others stall? The answer often lies in the earliest design decisions, where choices about samples, platforms and data determine what is possible later.
-
ArticleWorld ADC 2026: where antibody-drug conjugates are heading
At World ADC London 2026, experts highlighted how advances in payload design, targeting strategies and AI-driven discovery are changing antibody–drug conjugate development.
-
NewsCat cancer study reveals targets for human drugs
A major international study has discovered genetic similarities between cancers in cats and humans, potentially helping to inform future drugs that could benefit both species.
-
NewsLario raises $2.4m for neurological drug development
Lario Therapeutics has secured $2.4 million in funding from The Michael J. Fox Foundation for Parkinson’s Research and Wellcome to accelerate development of its neuronal calcium channel platform.